动态对比增强MRI上低强化前列腺癌与高危患者不良结局相关:一项假说生成研究的结果
单机构回顾性队列纳入54例确诊6个月内行前列腺MRI的患者,用定量DCE将优势病灶分为低强化与高强化。低强化组进展时间更短(6.2 vs 24.8个月,p=0.05),单因素分析不良结局OR 6.79(95%CI 1.45-31.72,p=0.02),多因素分析OR 2.05(95%CI 0.30-13.72,p=0.47)。作者认为低强化前列腺癌患者预后可能更差。
要点
- 低强化病灶进展时间6.2个月,高强化病灶24.8个月,p=0.05
- 低强化组不良结局单因素OR 6.79(95%CI 1.45-31.72),多因素OR 2.05(95%CI 0.30-13.72)
- 低强化病灶更大(33.1 vs 19.1 mm,p<0.001),Ktrans和kep更低
核心结论
- 低强化前列腺癌患者可能比高强化肿瘤患者预后更差,该研究为假说生成性质。
研究设计与样本
- 单机构回顾性IRB批准队列研究,纳入2012年1月至2014年3月间确诊6个月内行前列腺MRI的54例男性;两名阅片者依据PI-RADS v2独立识别优势病灶,用定量DCE分析将病灶分为低强化或高强化(对照正常外周带)。
关键影像表现/征象
- 低强化组病灶平均大小33.1 mm,高强化组19.1 mm,p<0.001
- 低强化病灶平均Ktrans和kep低于高强化病灶(p=0.03和p=0.04),Ve值无差异(p=0.25)
- 低强化组平均PSA 87.6 ng/dL,高强化组24.8 ng/dL,p=0.01
- 低强化组平均PSA密度1.54,高强化组0.72,p=0.03
诊断标准与关键数值
- 以正常外周带为参照,定量DCE分析将优势病灶分类为低强化或高强化
- 低强化组进展时间6.2个月 vs 高强化组24.8个月,p=0.05
- 低强化组不良结局单因素OR 6.79(95%CI 1.45-31.72,p=0.02),多因素OR 2.05(95%CI 0.30-13.72,p=0.47)
- 低强化肿瘤更可能为中级别(Gleason 3+4和4+3)和高grade(Gleason≥4+4)前列腺癌,p=0.05
临床应用与阅片要点
- 作者认为低强化前列腺癌患者可能预后更差,该研究为假说生成研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the association of hypoenhancement on dynamic Contrast enhanced (DCE) with prostate cancer patient outcomes.
MATERIAL AND METHODS: This was a single-institution retrospective Institutional Review Board (IRB)-approved cohort study of 54 men who had prostate Magnetic Resonance Imaging (MRI) within 6 months of cancer diagnosis between 01/2012 to 03/2014. Two readers independently identified the dominant MRI-lesions utilizing Prostate Imaging-Reporting and Data System-version2- guidelines. These lesions were classified as hypoenhancing or hyperenhancing, compared to normal peripheral zone using quantitative DCE analysis. The t test for unequal sample sizes and the two-sample Wilcoxon rank-sum tests were used to compare groups. Logistic regression determined if DCE characteristics predict the development of metastases or prostate cancer death.
RESULTS: Time-to-progression was significantly shorter for hypoenhancing tumors (6.2 vs. 24.8 months, p = 0.05). Men with these lesions had a higher odds of having poor outcome (univariate logistic regression, odds ratio (OR) 6.79, 95% confidence interval (CI) 1.45-31.72, p = 0.02; multivariate analysis, OR 2.05, 95% CI 0.30-13.72, p = 0.47). Hypoenhancing tumors were larger (33.1 vs. 19.1 mm, p < 0.001) and more likely to be intermediate (Gleason scores 3 + 4 and 4 + 3) and high-grade (Gleason scores ≥ 4 + 4) prostate cancers (p = 0.05). Men in the hypoenhancing group had a higher mean prostate-specific antigen (PSA) value (87.6 vs. 24.8 ng/dL, p = 0.01) and PSA density (1.54 vs. 0.72, p = 0.03). The mean Ktrans and kep of hypoenhancing lesion were lower when compared to hyperenhancing lesions (p = 0.03 and p = 0.04). Ve values did not differ (p = 0.25).
CONCLUSION: Men with hypoenhancing prostate cancers may have a worse prognosis than men with hyperenhancing tumors.
引用
- Muglia VF, Reis RB, Rocha TO, et al. Hypoenhancing prostate cancers on dynamic contrast-enhanced MRI are associated with poor outcomes in high-risk patients: results of a hypothesis generating study. Abdom Radiol (NY). 2019. PMID: 30229422. doi:10.1007/s00261-018-1771-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。